Sangiovanni Timothy J. 4

4 · ZEVRA THERAPEUTICS, INC. · Filed Feb 2, 2026

AI-generated summary of this filing

Updated Feb 2, 2026

Zevra Therapeutics (ZVRA) SVP Timothy Sangiovanni Sells 1,750 Shares

What Happened

Timothy J. Sangiovanni, SVP Finance & Corporate Controller of Zevra Therapeutics (ZVRA), sold 1,750 shares in an open‑market transaction on Jan 30, 2026 for a weighted average price of $8.82 per share, totaling $15,442.
In connection with RSU vesting, the filing also shows conversions/exercises of restricted stock units into common shares on Jan 30 (6,333 shares) and Jan 31, 2026 (11,666 shares). Corresponding entries show disposals at $0.00 for 6,333 and 11,666 shares (reported as derivative dispositions).

Key Details

Transaction dates & prices: Jan 30, 2026 — open‑market sale of 1,750 shares at weighted avg $8.82 (trade prices ranged $8.62–$8.995); Jan 30 & Jan 31, 2026 — RSU conversions of 6,333 and 11,666 shares (reported as derivative exercises/conversions, code M).
Proceeds: Open‑market sale netted $15,442 (weighted average price reported).
Shares owned after transaction: Not specified in the excerpt provided.
Notable footnotes: F1 clarifies each RSU = right to one common share; F4/F5 describe vesting/settlement schedule (one‑third vested/settled on Jan 30/Jan 31 with remaining tranches per schedule); F2 notes a 10b5‑1 trading plan adopted 3/28/2025; F3 explains the open‑market sale was executed in multiple trades (prices ranged $8.62–$8.995).
Timeliness: Filing date 2026‑02‑02 for transactions dated Jan 30–31, 2026 — the filing appears to be timely.

Context

The derivative (M) entries correspond to RSUs vesting and converting into shares. The $0.00 disposal lines commonly reflect shares surrendered/settled in connection with the vesting (e.g., withholding or settlement mechanics); the footnotes state the RSUs vested and were settled on the listed dates.
The 1,750‑share sale was executed under a pre‑arranged 10b5‑1 plan (per footnote), which is a preplanned trading arrangement rather than an ad hoc open‑market sale.

Form 4

Period: 2026-01-30

SVP, Finance & Corp Controller

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-01-30+6,333→ 22,674 total
Sale
Common Stock
[F2][F3]
2026-01-30$8.82/sh−1,750$15,442→ 20,924 total
Exercise/Conversion
Common Stock
[F1]
2026-01-31+11,666→ 32,590 total
Exercise/Conversion
Restricted Stock Unit
[F1][F4]
2026-01-30−6,333→ 12,667 total
→ Common Stock (6,333 underlying)
Exercise/Conversion
Restricted Stock Unit
[F1][F5]
2026-01-31−11,666→ 11,668 total
→ Common Stock (11,666 underlying)

Footnotes (5)

[F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
[F2]Adoption date of referenced 10b5-1(c) plan is: 3/28/2025.
[F3]This transaction was executed in multiple trades at prices ranging from $8.62 to $8.995. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
[F4]One third of the restricted stock units vested and settled on January 30, 2026. The remaining two thirds of the shares will vest and settle in equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date.
[F5]One third of the restricted stock units vested and settled on each of January 31, 2025 and January 31, 2026. The remaining one third of the shares will vest and settle on January 31, 2027, subject to the Reporting person's continued service through such vesting date.

Signature

/s/ Timothy J. Sangiovanni|2026-02-02

1 file